Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

NEXT STORY
XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
PREV STORY
HealthLynked Streamlines Patient Check-in with the Release of its New Application for Healthcare Practices
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

NEXT STORY
XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
PREV STORY
HealthLynked Streamlines Patient Check-in with the Release of its New Application for Healthcare Practices
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

author_avatar
NASDAQ Market News

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology ...

author_avatar
NASDAQ Market News

Renalytix Convenes Expert Panel at VA Healthcare Summit

author_avatar
NASDAQ Market News